A pre-planned exploratory analysis of the ATOMIC study indicates that adding atezolizumab to chemotherapy provides no disease-free survival (DFS) benefit for colon cancer patients who receive fewer than six cycles of mFOLFOX6. While the primary ATOMIC trial demonstrated an 86.3% 3-year DFS rate with the immunotherapy-chemotherapy combination compared to 76.2% with chemotherapy alone, this subgroup analysis suggests treatment duration significantly influences outcomes.
How does chemotherapy duration affect immunotherapy outcomes?
According to findings presented at the ESMO Gastrointestinal Cancers Congress 2026, the efficacy of atezolizumab is linked to the length of the chemotherapy course. Patients who underwent more than six cycles of mFOLFOX6 saw improved 3-year DFS when adding atezolizumab (adjusted hazard ratio [aHR] 0.45; 95% CI 0.29–0.71). Conversely, those receiving fewer than six cycles showed no significant benefit from the addition of the immunotherapy (aHR 0.84; 95% CI 0.35–2.01).
The ATOMIC trial protocol was designed before the international duration evaluation of adjuvant therapy (IDEA) collaboration results were reported.
Why are these results considered hypothesis-generating?
Dr. Guillem Argilés of the Memorial Sloan Kettering Cancer Center, New York, USA, notes that while the data are interesting, they are difficult to interpret and serve only as hypothesis-generating. He points out that the original ATOMIC study design—which compared atezolizumab combined with mFOLFOX for 6 months plus atezolizumab continued as monotherapy for a total of 12 months of therapy, with mFOLFOX6 alone for 6 months—was complicated by patients failing to complete the 6 months of treatment due to toxicity or concomitant health events that precluded the completion of the trial protocol.
“There can be a myriad of possible confounding factors that may have contributed to the reported observation,” Dr. Argilés stated. Because the trial occurred over several years, the standard of care also shifted, with 3 months of CAPOX replacing the previous recommendation for 6 months of FOLFOX for low- and medium-risk patients during the study period.
What is the future of dMMR colon cancer treatment?
The clinical focus is shifting toward determining whether adjuvant or neoadjuvant therapy offers superior outcomes. Currently, the phase II ANTONIO trial (NCT05118724) is prospectively evaluating adjuvant treatment with immunotherapy alone for patients with high-risk stage II or III dMMR colorectal cancer ineligible for oxaliplatin-based chemotherapy.
Dr. Argilés suggests that the ANTONIO trial will likely clarify the core questions raised by the ATOMIC analysis. The medical community continues to face challenges in standardizing care for dMMR colon cancer as treatment approaches evolve from traditional chemotherapy toward immunotherapy-based strategies.
When reviewing clinical trial data, always check if the study protocol was updated to reflect changes in the standard of care.
Frequently Asked Questions
Does atezolizumab always improve survival in dMMR colon cancer?
No. According to the ATOMIC study analysis, the benefit is dependent on the duration of the chemotherapy regimen. No DFS benefit was observed in patients who received fewer than six cycles of mFOLFOX6.
What is the status of the ANTONIO trial?
The ANTONIO trial (NCT05118724) is a phase II study currently evaluating adjuvant immunotherapy as a standalone treatment for high-risk stage II or III dMMR colorectal cancer patients ineligible for oxaliplatin-based chemotherapy.
Why did some patients in the ATOMIC trial not complete treatment?
As noted by Dr. Argilés, patients did not complete the 6 months of treatment due to toxicity or concomitant health events that precluded the completion of the trial protocol.
Are you a healthcare professional interested in the latest oncology research? Subscribe to our newsletter for updates on the latest phase II and III clinical trial results.
